Candel Therapeutics CADL Stock
Candel Therapeutics Price Chart
Candel Therapeutics CADL Financial and Trading Overview
| Candel Therapeutics stock price | 4.82 USD |
| Previous Close | 1.55 USD |
| Open | 1.63 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 1000 |
| Day's Range | 1.43 - 1.63 USD |
| 52 Week Range | 1.15 - 4.25 USD |
| Volume | 18.38K USD |
| Avg. Volume | 31.36K USD |
| Market Cap | 41.36M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.74 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.2 USD |
CADL Valuation Measures
| Enterprise Value | 8.36M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6436781 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 439.95013 |
| Price/Book (mrq) | 1.0430342 |
| Enterprise Value/Revenue | 88.901 |
| Enterprise Value/EBITDA | -0.242 |
Trading Information
Candel Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -58.78% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.25 USD |
| 52 Week Low | 1.15 USD |
| 50-Day Moving Average | 1.52 USD |
| 200-Day Moving Average | 2.02 USD |
CADL Share Statistics
| Avg. Volume (3 month) | 31.36K USD |
| Avg. Daily Volume (10-Days) | 21.54K USD |
| Shares Outstanding | 28.92M |
| Float | 17.97M |
| Short Ratio | 5.72 |
| % Held by Insiders | 34.59% |
| % Held by Institutions | 19.88% |
| Shares Short | 125.01K |
| Short % of Float | 0.64% |
| Short % of Shares Outstanding | 0.42% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -37626.59% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.19% |
| Return on Equity (ttm) | -51.66% |
Income Statement
| Revenue (ttm) | 94K USD |
| Revenue Per Share (ttm) | 0.003 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -20662000 USD |
| EBITDA | -34526000 USD |
| Net Income Avi to Common (ttm) | -26715000 USD |
| Diluted EPS (ttm) | -0.9 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 59.26M USD |
| Total Cash Per Share (mrq) | 2.05 USD |
| Total Debt (mrq) | 22.79M USD |
| Total Debt/Equity (mrq) | 57.47 USD |
| Current Ratio (mrq) | 11.817 |
| Book Value Per Share (mrq) | 1.371 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -34185000 USD |
| Levered Free Cash Flow (ttm) | -22669500 USD |
Profile of Candel Therapeutics
| Country | United States |
| State | MA |
| City | Needham |
| Address | 117 Kendrick Street |
| ZIP | 02494 |
| Phone | 617 916 5445 |
| Website | https://www.candeltx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 76 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
Q&A For Candel Therapeutics Stock
What is a current CADL stock price?
Candel Therapeutics CADL stock price today per share is 4.82 USD.
How to purchase Candel Therapeutics stock?
You can buy CADL shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Candel Therapeutics?
The stock symbol or ticker of Candel Therapeutics is CADL.
Which industry does the Candel Therapeutics company belong to?
The Candel Therapeutics industry is Biotechnology.
How many shares does Candel Therapeutics have in circulation?
The max supply of Candel Therapeutics shares is 47.24M.
What is Candel Therapeutics Price to Earnings Ratio (PE Ratio)?
Candel Therapeutics PE Ratio is now.
What was Candel Therapeutics earnings per share over the trailing 12 months (TTM)?
Candel Therapeutics EPS is -1.74 USD over the trailing 12 months.
Which sector does the Candel Therapeutics company belong to?
The Candel Therapeutics sector is Healthcare.
Candel Therapeutics CADL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}